Multiple Sclerosis - Epidemiology Forecast to 2032

DelveInsight’s "Multiple Sclerosis–Epidemiology Forecast–2032" report delivers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Multiple Sclerosis Disease Understanding
Multiple sclerosis (MS) is the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. Multiple Sclerosis attacks the axons of the central nervous system, which are protected by myelin, commonly known as white matter.
Multiple Sclerosis is a chronic disease that affects people differently. A small number of those with Multiple Sclerosis will have a mild course with little to no disability, whereas others will have a steadily worsening disease that increases disability over time. Most people with Multiple Sclerosis, however, will have short periods of symptoms followed by long stretches of relative quiescence (inactivity or dormancy), with partial or full recovery. Women are affected more frequently with Multiple Sclerosis compared to men. The disease is rarely fatal, and most people with Multiple Sclerosis have a normal life expectancy. New treatments can reduce long-term disability for many people with Multiple Sclerosis.
There are several rare and unusual types of Multiple Sclerosis. One of them is the Marburg Multiple Sclerosis variant (also known as malignant Multiple Sclerosis), which causes rapid and unstoppable symptoms and dysfunction, leading to severe disability and death shortly after the onset of the disease. Baro’s concentric sclerosis, which causes the concentric rings of myelin destruction seen on MRI, is another variant of Multiple Sclerosis that can progress rapidly.
Weakness, stiffness, and cramps can be severe enough to affect walking and standing. In some cases, Multiple Sclerosis causes partial or total paralysis, and the use of wheelchairs is not uncommon, especially for untreated and advanced illnesses. Many people with multiple sclerosis find that fever exacerbates their weakness and malaise; exacerbations of MS can occur after frequent infections.
There is no single test used to diagnose Multiple Sclerosis. The disease is confirmed when symptoms and signs develop and are related to different parts of the nervous system at more than one interval in time and after other alternative diagnoses have been excluded.
Doctors use different tests to rule out or confirm the diagnosis. In addition to complete medical history, physical examination, and a detailed neurological examination, a doctor may recommend:
• MRI scans of the brain and spinal cord to look for the characteristic lesions of Multiple Sclerosis. A special dye or contrast agent may be injected into a vein to enhance brain images of the active Multiple Sclerosis lesions.
• Lumbar puncture (sometimes called a spinal tap) to obtain a sample of cerebrospinal fluid and examine it for proteins and inflammatory cells associated with the disease. Spinal tap analysis also can rule out diseases that may look like Multiple Sclerosis.
There is no cure for Multiple Sclerosis, but there are a wide range of treatment options that improve the long-term outcome in patients. Without treatment, most patients will worsen over time. The goal of Multiple Sclerosis therapy is to reduce relapses and improve and sustain functionality throughout the patient’s life. Treatment of Multiple Sclerosis has two aspects: disease-modifying therapy (DMT) for the underlying immune disorder, and therapies to relieve or modify symptoms. Disease-modifying agents are directed towards reducing the frequency of relapses and slowing progression. DMT has been approved for use only in relapsing forms of Multiple Sclerosis. Among patients with Multiple Sclerosis who switched to DMTs, persistence was consistently low regardless of treatment. Although persistence with oral DMTs was slightly higher than with injectable DMTs, overall results indicate poor persistence to second-line therapy and highlight the need to improve long-term persistence with DMTs.
Multiple Sclerosis Epidemiology
The Multiple Sclerosis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Multiple Sclerosis epidemiology segmented as the Total Prevalent Cases of Multiple Sclerosis, Prevalence of Multiple Sclerosis based on Gender, Phenotype specific prevalent cases of Multiple Sclerosis, Prevalence of Multiple Sclerosis based on Age, EDSS. The report includes the Prevalent scenario of Multiple Sclerosis in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Multiple Sclerosis Epidemiology
The epidemiology segment also provides the Multiple Sclerosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent population of Multiple Sclerosis associated in 7MM countries was estimated to be 1,265,234 cases in 2020 and expected to increase at a CAGR of 0.42% for the study period, i.e., 2019–2032.
• As per the estimates, US has the highest prevalent population of Multiple Sclerosis in 7MM.
Among the EU5 countries, Germany had the highest prevalent population of Multiple Sclerosis. On the other hand, Spain had the lowest number of case, 45,194 cases in 2020.
Scope of the Report
• Multiple Sclerosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Multiple Sclerosis Epidemiology Report and Model provide an overview of the risk factors and global trends of Multiple Sclerosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Multiple Sclerosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Multiple Sclerosis.
• The report provides the segmentation of the Multiple Sclerosis epidemiology by prevalent Cases of Multiple Sclerosis in 7MM.
• The report provides the segmentation of the Multiple Sclerosis epidemiology by Prevalence of Multiple Sclerosis, Prevalence of Multiple Sclerosis based on Etiology specific factors, Age-specific cases of Multiple Sclerosis in 7MM.

Report Highlights
• 11-year Forecast of Multiple Sclerosis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Multiple Sclerosis
• Prevalent Cases of Multiple Sclerosis based on Gender
• Phenotype specific Prevalent cases of Multiple Sclerosis
• Prevalence of Multiple Sclerosis based on Age
• EDSS

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population about Multiple Sclerosis?
• What are the key Findings of Multiple Sclerosis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
• What would be the total number of patients with Multiple Sclerosis across the 7MM during the forecast period (2019–2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019–2032)?
• What are the disease risk, burden, and unmet needs of Multiple Sclerosis?
• What are the currently available treatments for Multiple Sclerosis?

Reasons to buy
The Multiple Sclerosis Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Multiple Sclerosis market
• Quantify patient populations in the global Multiple Sclerosis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Multiple Sclerosis therapeutics in each of the markets covered
• Understand the magnitude of Multiple Sclerosis population by its prevalent cases
• Understand the magnitude of Multiple Sclerosis population by its clinical manifestation specific cases
• The Multiple Sclerosis epidemiology report and model was written and developed by Masters and PhD level epidemiologists
• The Multiple Sclerosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 12-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032